Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Gefitinib 9Pemetrexed 7Carboplatin 5Gemcitabine 4Cisplatin 4apatinib 3Docetaxel 3aflutinib 2Neoadjuvant Therapy 2Erlotinib Hydrochloride 2Bevacizumab 2tislelizumab 1pembrolizumab 1motesanib diphosphate 1lometrexol 1icotinib 1endostar protein 1camrelizumab 1Watchful Waiting 1Thymalfasin 1Radiomics 1Platinum Compounds 1Paclitaxel 1Lymph Node Excision 1Indium 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Folic Acid 1Exome 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma of Lung × lometrexol × Clear all
NCT00033722 2014-01-06

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡